Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mod GRF 1-29

Sermorelin, Growth Hormone Releasing Hormone (1-29), hGRF(1-29)NH2

Quick Stats
Studies 227
Trials 47
Score 2
1987 pubmed 16 citations

Nine months' subcutaneous therapy with synthetic growth hormone releasing factor in children with short stature.

Hümmelink. R R; Rohwedder. R R; Sippell. W G WG

Key Findings

  • Twice‑daily low‑dose GRF‑1‑29 increased leg growth rate more than once‑daily low‑dose.
  • A higher single daily dose (8‑10 µg/kg) also produced a modest boost in growth.
  • Overall yearly height gain rose from ~4.9 cm to ~6.0 cm, though the difference was not statistically significant.

Practical Outcomes

  • For biohackers, the data suggest that higher doses or more frequent GRF‑1‑29 injections can modestly amplify growth‑hormone activity, but the study’s relevance to healthy adults is unclear. Use caution: the safety profile in children with GH deficiency may not translate to adult longevity or performance goals, and larger, controlled trials are needed before adopting any protocol.

Summary

A small study gave nine boys with short stature synthetic growth‑hormone‑releasing factor (GRF‑1‑29) under different dosing schedules. More frequent injections (twice a day) and higher doses led to slightly faster growth of the legs and overall height, but the changes were modest and the study was done in children with growth hormone deficiencies, not healthy adults.

Abstract

The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months. Their short stature was due to partial hGH deficiency/hGH neurosecretory dysfunction and was diagnosed by arginine and insulin stimulation tests and hGH nocturnal profiles. Four patients (Group I) were given GRF, 3-4 micrograms/kg s.c. b.d. during the first period of 3 months, and after an interval of 1 month, the same dose once daily during the second treatment period of 3 months. Five patients (Group II) were given GRF, 3-4 micrograms/kg s.c., once daily during the first and b.d. during the second 3 months of therapy. After a second interval of 1 month without any GRF treatment, the third 3-month period for both groups consisted of one daily injection of GRF, 8-10 micrograms/kg s.c. at 19.00 hours. Total body height and lower leg length were measured by stadiometry and knemometry, respectively. GRF intravenous bolus tests were performed in each patient following fasting, before and at the end of the first and second 3-month periods. Serum IGF-1 and urinary hydroxyproline excretion were determined monthly. Stadiometric growth rate, determined over the whole study period of 11 months including the treatment-free intervals, increased from 4.92 cm/year to 5.97 cm/year (p greater than 0.05). Mean knemometric growth rates increased from 0.28 mm/week before therapy, to 0.35 mm/week during the one injection/day period at low dose, to 0.39 mm/week (p less than 0.05) during the b.d. period, and to 0.40 mm/week during the last 3 months of high-dose GRF given once daily.(ABSTRACT TRUNCATED AT 250 WORDS)

Study Information

Provider

pubmed

Year

1987

Date

1987-01-01T00:00:00.000Z

DOI

10.1111/j.1651-2227.1987.tb17098.x

Citations

16

References

15